Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;8(15):960.
doi: 10.21037/atm.2020.03.155.

Transcatheter aortic valve replacement (TAVR): expanding indications to low-risk patients

Hector Cubero-Gallego  1   2 , Christian Dam  3 , Juan Meca  1 , Pablo Avanzas  1   2   4
Affiliations
Review

Transcatheter aortic valve replacement (TAVR): expanding indications to low-risk patients

Hector Cubero-Gallego et al. Ann Transl Med. 2020 Aug.

Abstract

Aortic stenosis (AS) is the most common cardiac valve disease in developed countries. Transcatheter aortic valve replacement (TAVR) for the treatment of severe symptomatic AS is an accepted therapy option for elderly patients with symptomatic severe AS. Nowadays, TAVR has revolutionized the treatment of AS with an exponential growth worldwide. Both the development of new generation valves and the experience of the operating teams have contributed significantly to decrease the complications rate after TAVR. Several randomized trials have reported similar short- and mid-term results, and even better than surgical aortic valve replacement (SAVR) in patients with high- or intermediate-risk. In addition, two comparison trials in low-risk patients have reported promising results. Therefore, in the future TAVR indications will expand, treating younger and younger patients, with less comorbidities and lower risk. However, the long-term durability of percutaneous prostheses is a matter of debate. The aim of this manuscript is to review available data that support to treat AS in low-risk patients and provide our perspective on the topic.

Keywords: Aortic stenosis (AS); low surgical risk; surgical aortic calva replacement; transcatheter aortic valve replacement (TAVR).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.155). The series “Structural Heart Disease: The Revolution” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

References

    1. Eveborn GW, Schirmer H, Heggelund G, et al. The evolving epidemiology of valvular aortic stenosis. the Tromsøstudy. Heart 2013;99:396. 10.1136/heartjnl-2012-302265 - DOI - PubMed
    1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006-8. 10.1161/01.CIR.0000047200.36165.B8 - DOI - PubMed
    1. Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group , ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-91. 10.1093/eurheartj/ehx391 - DOI - PubMed
    1. Auffret V, Lefèvre T, Van Belle E, et al. Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI. JACC 2017;70:42-55. 10.1016/j.jacc.2017.04.053 - DOI - PubMed
    1. Durand E, Borz B, Godin M, et al. Transfemoral aortic valve replacement with the Edwards SAPIEN and Edwards SAPIEN XT prosthesis using exclusively local anesthesia and fluoroscopic guidance: feasibility and 30-day outcomes. JACC Cardiovasc Interv 2012;5:461-7. 10.1016/j.jcin.2012.01.018 - DOI - PubMed